



■ TEL. : 022 - 6825 2525
■ FAX : 022 - 2405 7708
■ E-Mail : info@naxparlab.com
■ Visit us at: www.naxparlab.com
■ CIN No. : L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

Date: 14.02.2020

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Sub: Submission of Un-Audited Standalone and Consolidated Financial Results for quarter and nine months ended 31st December, 2019 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref: Parnax Lab Limited, Script Code- 506128

Dear Sir,

Kindly find enclosed herewith the following:


1. A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter and nine months ended 31st December 2019;

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

For PARNAX LAB LIMITED



PRAKASH SHAH
DIRECTOR
DIN: 00440980
Encl: As above

Works : Plot No. 120, Masat Ind. Estate, Dadra & Nagar Haveli, Silvassa-396230 (India)
Plot No. 121 & 74, Masat Ind. Estate, Dadra & Nagar Haveli, Silvassa-396230 (India)
Phone : 0260 - 2640644 / 2641066 • Fax : 0260-2640655 • E-mail : naxpar@gamil.com

LADHA SINGHAL & ASSOCIATES
CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Parnax Lab Limited** ("the company") for the quarter and nine months ended December 31st, 2019 together with the relevant notes thereon ("the Statement"). The Statement being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates
Chartered Accountants
(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)
Partner
M. No. : 104151
Place : Mumbai
Dated : 14th February, 2020



UDIN: 20104151 AAAABG 9221

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN:-L36912MH1982PLC027925


STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2019

S. No.	Particulars	(Rs. In Lakhs)					
		Unaudited Current Quarter Ended 31.12.2019	Unaudited Previous Quarter ended 30.09.2019	Unaudited Correspondi ng Quarter Ended 31.12.2018	Unaudited Current Nine Months Ended 31.12.2019	Unaudited Correspondi ng Nine Months Ended 31.12.2018	Audited Year Ended 31.03.2019
I	Revenue from Operations	214.31	178.09	122.66	538.42	491.78	649.26
II	Other Income	11.24	7.06	13.93	25.55	38.75	51.21
III	Total Revenue (I+II)	225.55	185.15	136.59	563.97	530.53	700.47
IV	Expenses						
	a) Cost of Material Consumed	93.08	52.96	40.45	196.29	178.41	235.34
	b) Purchase of Stock in trade	25.03	55.21	8.66	114.30	61.08	83.09
	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	-	-	-	-
	d) Employee benefit expenses	14.62	12.62	13.58	39.08	34.71	45.09
	e) Finance Cost	21.68	70.41	27.44	116.88	80.99	107.96
	f) Depreciation and amortisation expenses	1.10	1.10	1.22	3.30	3.65	4.84
	g) Other expenses	70.61	51.11	72.25	165.33	211.46	274.99
	h) Impairment of assets classified as held for disposal	-	-	-	-	-	-
	Total Expenses (IV)	226.12	243.41	163.60	635.18	570.30	751.31
V	Profit/(loss) before exceptional items and tax (III-IV)	(0.57)	(58.26)	(27.01)	(71.21)	(39.77)	(50.84)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	(0.57)	(58.26)	(27.01)	(71.21)	(39.77)	(50.84)
VIII	Tax expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	31.90
	c) Short/(Excess) Prov for Tax for Earlier Years	-	-	-	-	-	-
IX	Profit/ (Loss) for the period (VII-VIII)	(0.57)	(58.26)	(27.01)	(71.21)	(39.77)	(82.74)
X	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(0.02)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	-	-	-	-	(0.02)
XII	Total Comprehensive Income comprising profit & other comprehensive income for the period (VII+IX)	(0.57)	(58.26)	(27.01)	(71.21)	(39.77)	(82.76)
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIV	Earning per equity share (Not Annualised)						
	(1) Basic	(0.01)	(0.69)	(0.32)	(0.84)	(0.47)	(0.97)
	(2) Diluted	(0.01)	(0.69)	(0.32)	(0.84)	(0.47)	(0.97)

Notes-

1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 14, 2020
2	The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and nine months ended December 31, 2019.
3	EPS for quarter ended is on non annualised basis.
4	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
5	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai
Date : 14-02-2020



By Order of the Board
For Parnax Lab Limited

(Signature)

Prakash M Shah
Whole Time Director & CEO
DIN NO: 00440980

LADHA SINGHAL & ASSOCIATES
CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8, Jogani Industrial Complex,
Chunabhatti, Mumbai - 400 022

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** ("the Parent") and **Naxpar Pharma Private Limited** ("the Subsidiary") (the Parent and its subsidiary together referred to as "the Group") for the quarter and Nine months ended December 31st, 2019 together with the relevant notes thereon ("the Statement"). The Statement submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The Statement is the responsibility of the Parent's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended, to the extent applicable.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates
Chartered Accountants
(FRN: 120241W)

Vinod Ladha
(Vinod Ladha)
Partner
M. No. : 104151
Place : Mumbai
Dated : 14th February, 2020



UPEN: 20104151 AAAABH 8217

PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.
Tel : 022 - 68252525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com
CIN-L38912MH1982PLC027025


STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31.12.2019

(Rs. in Lakhs)

S. No.	Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		Current Quarter Ended 31.12.2019	Previous Quarter ended 30.09.2019	Correspondin g Quarter Ended 31.12.2018	Current Nine Months Ended 31.12.2019	Correspondin g Nine Months Ended 31.12.2018	Current Year Ended 31.03.2019
I	Revenue from Operations	2,545.84	2,570.39	2,331.21	7,182.58	8,864.45	10,878.00
II	Other Income	12.05	9.04	52.78	28.59	143.29	211.02
III	Total Revenue (I+II)	2,557.89	2,579.43	2,383.99	7,211.17	9,007.74	11,089.02
IV	Expenses						
a)	Cost of Material Consumed	1,394.21	1,174.57	1,086.48	3,407.89	3,379.26	4,391.98
b)	Purchase of Stock in trade	1.42	78.36	84.44	86.80	856.01	901.57
c)	Changes in inventories of finished goods, Work in progress and stock in trade	(158.79)	(38.85)	(1.85)	(158.79)	35.63	(22.08)
d)	Employee benefits expenses	385.31	335.85	338.34	1,079.05	1,008.56	1,306.04
e)	Finance Cost	108.95	138.37	104.04	348.81	283.16	388.78
f)	Depreciation and amortisation expenses	107.22	107.30	94.26	320.19	277.92	382.35
g)	Other expenses	802.02	747.96	634.63	2,106.48	2,635.25	3,278.41
h)	Impairment of assets classified as held for disposal	-	-	-	-	-	-
	Total Expenses (IV)	2,640.34	2,543.56	2,340.32	7,250.43	8,475.79	10,627.03
V	Profit/(loss) before exceptional items and tax (III-IV)	(82.45)	35.87	43.67	(39.26)	531.95	461.99
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	(82.45)	35.87	43.67	(39.26)	531.95	461.99
VIII	Tax expense						
a)	Current Tax	-	-	-	-	-	120.00
b)	Deferred Tax	-	-	-	-	-	6.74
c)	Short (Excess) Prov for Tax for Earlier Years	-	-	4.71	(4.40)	4.71	4.71
IX	Profit/(Loss) for the period (VII-VIII)	(82.45)	35.87	38.96	(34.86)	527.24	330.54
X	Minority Interest Profit (Loss)	(0.16)	0.20	0.13	0.07	1.13	0.66
XI	Profit/(Loss) After Share of Profit (Loss) of minority interest	(82.29)	35.67	38.83	(34.93)	526.11	329.88
XII	Other Comprehensive Income						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(8.00)
(a)	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B.	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(a)	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XIII	Total Other Comprehensive Income for the period	-	-	-	-	-	(8.00)
XIV	Total Comprehensive Income comprising profit and other comprehensive income for the period (IX+XIII)	(82.29)	35.67	38.83	(34.86)	527.24	321.88
XV	Total profit/(loss) for the year attributable to:						
-	Owners of the Company	(82.29)	35.67	38.83	(34.93)	526.11	329.88
-	Non-controlling interests	(0.16)	0.20	0.13	0.07	1.13	0.68
XVI	Other Comprehensive Income attributable to:						
-	Owners of the Company	-	-	-	-	-	(7.98)
-	Non-controlling interests	-	-	-	-	-	(0.02)
XVII	Total Comprehensive income attributable to:						
-	Owners of the Company	(82.29)	35.67	38.83	(34.93)	526.11	321.90
-	Non-controlling interests	(0.16)	0.20	0.13	0.07	1.13	0.64
XVIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIX	Earning per equity share (Not Annualised)						
(1)	Basic	(0.97)	0.42	0.46	(0.41)	6.20	3.89
(2)	Diluted	(0.97)	0.42	0.46	(0.41)	6.20	3.89

Notes-

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 14, 2020
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and Nine Months ended December 31, 2019
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.



By Order of the Board
Parnax Lab Limited
Prakash M Shah
Prakash M Shah
Whole Time Director & CEO
DIN NO: 00440980

Place : Mumbai
Date : 14-02-2020